WeVote
Log In

Bill

Bill

HR 9699

Drug Deal Disclosure Act

119th Congress Introduced by André Carson and 23 co-sponsors

The bill would require mandatory disclosures of drug pricing deals and related financial arrangements to increase transparency into how medications are priced and bought.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 9699

Overview

HR 9699, titled the Drug Deal Disclosure Act, is a bill introduced in the 119th Congress. The sponsors’ list includes a broad set of House Democrats. The measure was referred to the House Committees on Energy and Commerce, Ways and Means, and the Budget for consideration of provisions within their jurisdiction.

Purpose and intent

  • The bill aims to address transparency around drug distribution and pricing by requiring disclosure related to drug deals, pricing arrangements, or other related activities within the pharmaceutical and healthcare sectors.
  • The core objective appears to be enhancing visibility into transactions that could influence medication costs or access, potentially informing policy decisions, enforcement, and consumer protection.

Key provisions (as implied by title and typical scope)

While the exact text is not provided here, the Drug Deal Disclosure Act would likely include:
- Mandatory disclosures of certain drug-related pricing data, rebates, discounts, or financial arrangements between drug manufacturers, wholesalers, distributors, and health plans or purchasers.
- Requirements for reporting entities to submit periodic (e.g., annual or quarterly) disclosures to a designated federal agency.
- Definitions clarifying which entities and which types of deals are subject to disclosure (e.g., drug manufacturers, wholesalers, pharmacy benefit managers, health plans, or large purchasers).
- Provisions for the accessibility of disclosed information, potentially through a public database or agency reports, while considering confidentiality protections for competitively sensitive information.
- Penalties or enforcement mechanisms for non-compliance, including timing or completeness of disclosures.
- Possible coordination with federal budget and fiscal analyses, given the involvement of Ways and Means and the Budget committees.

Who would be affected

  • Drug manufacturers and developers of pharmaceutical products.
  • Wholesalers and distributors involved in the supply chain for prescription medications.
  • Pharmacy Benefit Managers (PBMs) and health plans that negotiate rebates, discounts, or other financial arrangements.
  • Large purchasers, including hospital systems, integrated delivery networks, and group purchasers.
  • Potentially patients and consumers through greater price transparency and potential impacts on drug pricing dynamics.

Procedural and timeline aspects

  • Legislative action room: Referred to multiple committees (Energy and Commerce; Ways and Means; Budget) for jurisdiction-specific provisions.
  • The timeline for committee consideration is “to be subsequently determined by the Speaker,” indicating ongoing procedural scheduling.
  • As a bill introduced in July 2026, it would need consideration, potential amendments, and passage by the House, followed by potential action in the Senate and confirmation/Presidential approval to become law.

Potential impact and considerations

  • Increased transparency around drug pricing and deal structures could inform policymakers, payers, and the public regarding drivers of drug costs.
  • Data availability might enable enforcement against unfair or deceptive pricing practices, while raising concerns about the handling of sensitive commercial information.
  • The efficacy of the policy would depend on the scope of disclosures, data granularity, and the balance between transparency and confidentiality.

If you’d like, I can tailor this summary to a specific audience (e.g., policy staff, advocacy groups, or industry stakeholders) or add a proposed outline of potential reporting formats and data elements based on common drug pricing disclosure frameworks.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.